about
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and f...
Read More
39.04
0.35
(0.90%)
1.6M
XNAS Volume
XNAS 26 Sep, 2025 5:30 PM (EDT)
High Financial Strength
Mid Valuation
Technically Neutral
Mid-range Performer
These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest.
View Similar
Embed DVM
Exelixis Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..